DIABETES: New Insights into Therapeutic Strategies. Lisa Ellard, MSN,CRNP, CDE

Similar documents
Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

SGLT2 Inhibitors

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

SGLT2 Inhibitors

Oral and Injectable Non-insulin Antihyperglycemic Agents

What s New in Diabetes Medications. Jena Torpin, PharmD

SGLT2 Inhibitors

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Drug Class Monograph

Diabetes Mellitus II CPG

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Drug Class Review Newer Diabetes Medications and Combinations

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

SGLT2 Inhibitors

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

New Therapies for Diabetes

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

The Death of Sulfonylureas? A Review of New Diabetes Medications

GLYXAMBI (empagliflozin-linagliptin) oral tablet

Diabetes Medications: Oral Anti-Hyperglycemic Medications

AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. Sherwin D Souza, MD, FACE

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

Date of Review: September 2016 Date of Last Review: September 2015

What s New in Type 2 Diabetes? 2018 Diabetes Updates

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists

Rebecca Newberry APRN MS CDE

How can we improve outcomes in Type 2 diabetes?

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Antidiabetic Agents CHAPTER BIGUANIDES

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Drug Class Review Monograph GPI Class 27 Anti-diabetics

1990 Obestiy

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Non-Insulin Diabetes Medications Summary

Fee-for-Service Pharmacy Provider Notice #216 ** March 2016 PDL Changes ** Existing Drug Classes

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

Very Practical Tips for Managing Type 2 Diabetes

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017

Diabetes 2016: Strategies for achieving optimal diabetes control

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION GLYXAMBI TM. empagliflozin and linagliptin tablets. 10 mg/5 mg and 25 mg/5 mg

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

STEP THERAPY CRITERIA

Faculty Disclosure. Type 2 Diabetes: Making Sense of New Therapies. Educational Need/ Practice Gap. Objectives. Current Diabetes Prevalence Data

Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview

Diabetes Treatment Guidelines

Individualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD

Pharmacologic Agents for Treatment of Type 2 Diabetes

11/4/2014. Outline. Pharmacists Objectives. Diabetes Update: What s New in Pharmacy Technician Objectives. Overview: Type 2 Diabetes Mellitus

Advanced Practice Education Associates. Endocrine

A MONTHLY DOSE OF EDUCATION

Clinical Practice Guidelines

Collaborative Practice Agreement

I. General Considerations

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

What s New in Diabetes Treatment. Disclosures

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

PRESCRIBING INFORMATION (PI)

Diabetes School October 2016

Making Sense of New DM Therapies and Technologies

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Drug Class Monograph

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations

Remote attendees, please mute your phones as a courtesy thank you!

2018 Diabetes Summit Managing Diabetes: An Art and a Science

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

DM Fundamentals Class 4 Meds for Type 2

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. empagliflozin and linagliptin tablets

continuing education for pharmacists

PRESCRIBING INFORMATION (PI)

ENDOCRINOLOGY & THE OLDER ADULT

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Welcome to the PHASE Learning Community! October 31, 2018

Halting the Rise, Newest Non- Insulin Options for Lowering A1c

Halting the Rise, Newest Non- Insulin Options for Lowering A1c

Drug Class Monograph

Brand name: Steglatro. Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck

*Sections or subsections omitted from the full prescribing information are not listed.

Transcription:

DIABETES: New Insights into Therapetic Strategies Lisa Ellard, MSN,CRNP, CDE

NEW, IMPROVED, ME TOO, & NOT ALONE New: Sodim-glcose co-transporter 2 Inhibitors (SGLT 2) Improved: Inslins Delivery, Dration, and Dosing Me Too: More Dipeptidyl Peptidase 4 Inhibitors (DPP4) & More Glcagon-like peptide-1 Mimetics (GLP1) Not Alone: New Combinations of Oral Diabetic Medications

SGLT2 INHIBITOR MEDICATIONS: A NEW CLASS OF DRUGS

SGLT2 INHIBITOR MECHANISM OF ACTION

SGLT2 INHIBITOR BENEFITS Decrease in A1c Decrease in Blood Pressre Decrease in Weight

SGLT2 INHIBITOR CONTRAINDICATIONS Severe Renal Impairment (egfr <30ml) [Invokana & Jardiance (egfr =/> 45ml) Farxiga (egfr =/>60)] End Stage Renal Disease Dialysis Type 1 Diabetes History of Diabetic Ketoacidosis Pregnancy and Nrsing Mothers Children < 18 years old

SGLT2 INHIBITOR WARNINGS AND PRECAUTIONS Hypotension Ketoacidosis Impaired Renal Fnction Urosepsis & Pyelonephritis Hypoglycemia Genital Mycotic Infections Elevated LDL-C Bladder Cancer (Farxiga) Bone Fractres (Invokana)

SGLT2 INHIBITOR POSSIBLE SIDE EFFECTS * Genital Mycotic Infections * Urinary Tract Infections * Increased Urination Ketoacidosis Hyperkalemia Elevated Creatinine Dehydration Impaired Renal Fnction Elevated LDL-C Hypotension Increased Risk of Bone Fractres (Invokana) Increased Risk of Bladder Cancer (Farxiga)

INSULIN THERAPY: IMPROVEMENTS New Delivery: Afrezza Inhaled Inslin Longer Dration: Tojeo & Tresiba New Doses: Hmalog Kwik Pen U200

NEW DELIVERY: INHALED INSULIN AFREZZA A rapid acting manmade inhaled inslin sed to control hyperglycemia in adlts with diabetes

AFREZZA BENEFITS No injections reqired Premeasred Cartridges Greater Bioavailability & Clearing Easy Portability

AFREZZA CONTRAINDICATIONS COPD Asthma Smoking Pregnancy & Breastfeeding Children (<18yo) DKA

AFREZZA WARNINGS AND PRECAUTIONS Acte Bronchospasms in patients with chronic lng disease Changes in Inslin Regimen Hypoglycemia Decreased Plmonary Fnction Hypokalemia Lng Cancer Diabetic Ketoacidosis Hypersensitivity

AFREZZA SIDE EFFECTS Hypoglycemia Bronchospasms Cogh Throat Irritation

INSULIN IMPROVEMENTS: LONGER DURATIONS

COMPARISONS OF LONGER DURATION Tojeo INSULINS Tresiba U300 concentration 450 nits per pen Available in boxes of 3 pens Unrefrigerated shelf life is 6 weeks Recommended to be given at same time of day Dration of action is p to 36 hors Transition to Tojeo from other long acting inslins is 1U:1U & 20% redction in Tojeo is recommended with transition from BID NPH Both U100 and U200 concentrations available U100 300 nits per pen (5/box) U200 600 nits per pen (3/box) Unrefrigerated shelf life is 8 weeks opened or nopened Recommended to be given same time of day once daily bt may delay by 16 hors if dose is missed Dration of action is p to 42 hors Transition to Tresiba from other long or immediate acting inslins is 1U:1U

NEW INSULIN DOSE: HUMALOG KWIK PEN U200 Available in boxes of boxes of 2 pens/600 nits per pen

DPP4-INHIBITORS & GLP-1 MIMETICS: ME TOO MEDICATIONS

DPP-4 INHIBITORS Janvia & Onglyza +PLUS+ Nesina - Available in 6.25, 12.5, & 25mg tablets Tradjenta - Available in 5mg tablets

GLP-1 MIMETICS Byetta and Victoza +PLUS+ Trlicity Available in.75 & 1.5mg Pens sq weekly Bydreon Available in 2mgs Pens & Syringes sq weekly Tanzem Available in 30 & 50mg Pens - sq weekly

COMBINATION ORAL DIABETES MEDICATIONS: NOT ALONE

Janmet XR Janvia+Metformin XR (100mg/1000mg, 50mg/500mg, & 50/1000mg) Jentadeto Tradjenta+Metformin (2.5mg/500mg, 2.5mg/850mg, & 2.5/1000mg) Synjardy Jardiance+Metformin (5mg/500mg, 5mg/1000mg 12.5/500mg, & 12.5/1000mg) Xigdo XR Farxiga+Metformin XR (5mg/500mg, 5mg/1000mg 10mg/500mg, & 10mg/1000mg) Kazano Nesina+Metformin (12.5mg/500mg, & 12.5mg/1000mg)

Detact Actos(TZD)+Amaryl(Slfonylrea) (30mg/2mg & 30mg/4mg) Oseni Nesina+Actos (25mg/15mg, 25mg/30mg 25mg/45mg, 12.5mg/15mg, 12.5mg/30mg, & 12.5mg/45mg Glyxambi Jardiance+Tradjenta (10mg/5mg & 25mg/5mg)

IN SUMMARY NEW CLASS OF DIABETES DRUGS SGLT2 INHIBITORS (Invokana, Farxiga, & Jardiance) IMPROVED DIABETES DRUGS Inslins (Afrezza, Tojeo, Tresiba, & Hmalog U200 Pen) ME TOO DIABETES DRUGS DPP-4 Inhibitors (Nesina & Tradjenta) GLP1 Mimetics (Trlicity, Bydreon, & Tanzem) NOT ALONE DIABETES DRUGS Combinations with Metformin (Janmet XR, Jentadeto, Synjardy, Xigdo XR, & Kazano) Combinations with Actos (Detact & Oseni) Other Combinations (Glyxambi)

THANK YOU